Tesamorelin before and after: what the trial data actually show

Last updated 2026-07-24

What does the tesamorelin evidence base actually cover?

Tesamorelin (brand name Egrifta) is FDA-approved for one specific thing: reduction of excess abdominal visceral fat in people with HIV-associated lipodystrophy ^[1][2]. That's it. The approval isn't for general fat loss, isn't for anti-aging, and isn't for bodybuilders chasing a leaner look. It's a growth hormone releasing hormone (GHRH) analogue that stimulates the pituitary to release the body's own growth hormone, which in turn drives lipolysis in visceral fat depots ^[2][3]. The core evidence is a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data, published in the Journal of Clinical Endocrinology and Metabolism in 2010 . That's the paper anyone doing real research should read first, not a forum thread of before-and-after photos. Everything downstream, meta-analyses, mechanistic studies, imaging substudies, traces back to that same population: HIV-positive adults with excess abdominal fat and lipodystrophy. Applying those numbers to someone without HIV, without lipodystrophy, chasing a flatter stomach for aesthetic reasons is extrapolation, not evidence. Be honest with yourself about which bucket you're in before you read the results section and assume it's your story too.

How long does it take to see results from tesamorelin?

In the phase 3 program, the primary endpoint was measured at 26 weeks (roughly 6 months), and that's the honest answer to how long results take . Some metabolic and inflammatory changes show up earlier. A study on inflammatory markers found reductions related to visceral fat loss appearing within the first three months of treatment, tracking alongside the fat reduction itself rather than lagging behind it . But the headline visceral fat reduction numbers, the ones people actually mean when they say 'tesamorelin peptide results', come from the 26-week endpoint. A meta-analysis of randomized controlled trials on tesamorelin's body composition, hepatic fat, and metabolic outcomes reinforces that the trial duration standard across this evidence base clusters around 26 to 52 weeks, not weeks two or four ^[4]. If someone tells you they saw dramatic before-and-after changes in three weeks, that's not what the trial data shows. Expect early signals (energy, sleep quality some users report anecdotally) well before you'd expect measurable visceral fat change on a scan.

How much visceral fat reduction is realistic to expect?

The pooled phase 3 data showed roughly a 15-18% relative reduction in visceral adipose tissue (VAT) versus placebo over 26 weeks, measured by CT scan . This isn't a number you feel by pinching your waist; it's a number a radiologist measures on a cross-sectional image. A separate analysis found that visceral fat reduction with tesamorelin correlated with improved liver enzymes in HIV, connecting the VAT drop to something clinically meaningful rather than cosmetic ^[5]. And a 2021 study reported that tesamorelin improves fat quality independent of changes in fat quantity, meaning some of the metabolic benefit isn't just 'less fat,' it's healthier fat tissue at a cellular level ^[6]. Worth being blunt here: this is visceral fat, the fat around your organs, not subcutaneous fat, the fat you can pinch. A person expecting their six-pack to appear because of tesamorelin is going to be disappointed. The trials never measured or promised that.

What do tesamorelin before and after pictures actually show (and what should you be skeptical of)?

If you go looking for tesamorelin peptide before and after pictures online, understand what you're looking at. The FDA trials measured visceral fat by CT scan, not by photograph . Visible waist circumference change was a secondary measure in some analyses, but it was modest compared to the internal VAT reduction. Many before-and-after photos circulating online come from off-label users stacking tesamorelin with other compounds, diet changes, or training programs, none of which isolates what tesamorelin itself is doing. A photo showing a dramatically flatter stomach after 8 weeks is not consistent with a drug whose own trials needed 26 weeks to show its primary effect. Be skeptical of any photo pair claiming rapid, dramatic transformation attributed to tesamorelin alone. That's not what the phase 3 evidence supports, and it's usually not what's actually happening in that photo.

Does tesamorelin help with liver fat, more than belly fat?

Yes, and this is arguably more interesting evidence than the waistline story. A randomized, double-blind, multicenter trial published in The Lancet HIV found tesamorelin reduced hepatic fat fraction in HIV-associated NAFLD (non-alcoholic fatty liver disease) compared to placebo ^[7]. Roughly a third of the treatment group showed resolution or significant improvement in liver fat over the trial period, a meaningfully different outcome than what people usually chase this peptide for. A hepatic transcriptomic study found tesamorelin changed gene expression signatures in the liver consistent with reduced fat accumulation and improved metabolic signaling ^[8]. A related proteomic and transcriptomic analysis mapped out specific response pathways involved in that hepatic fat reduction ^[9]. If your interest in tesamorelin is really about metabolic health markers rather than a visible transformation, the liver fat data is where the real substance is, more than the VAT number that gets quoted most often.

Does tesamorelin do anything for cognitive or neurocognitive outcomes?

There's a specific, narrow signal here worth naming precisely. A 2025 study in The Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity ^[10]. This is a targeted question in a targeted population, not a general claim that tesamorelin sharpens your thinking. Don't extrapolate this into a brain-fog cure or a nootropic use case. The study population is HIV-positive adults with abdominal obesity, and the endpoint is neurocognitive impairment specific to that population's known comorbidity profile. If you're not in that population, this finding tells you very little about what to expect for yourself.

What happens if you stop tesamorelin, do the results last?

The honest answer: durability data outside the HIV lipodystrophy trial extensions is thin. The phase 3 program included safety extension data, and the general pattern in GHRH analogue pharmacology is that effects depend on continued stimulation of endogenous GH release, meaning benefits tend to reverse once you stop . A pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects mapped out how the drug is cleared and how dosing needs vary by body weight and renal function, which matters for understanding why consistent dosing (not sporadic use) is how the trials achieved their results ^[11]. This isn't a drug where you take a short course and keep the benefit indefinitely; it works while GH stimulation continues. If you're weighing whether to start, factor in that this is very likely an ongoing-use therapy for as long as you want to maintain the visceral fat reduction, not a one-time reset.

How does tesamorelin perform in people on modern HIV regimens (integrase inhibitors)?

This matters because HIV treatment has changed a lot since the original phase 3 trials. A 2024 study in AIDS examined efficacy and safety of tesamorelin specifically in people with HIV on integrase inhibitors, a drug class that itself is associated with weight gain and metabolic changes ^[12]. This addresses a real gap: does tesamorelin still work the same way for a modern-regimen patient population, more than the population studied in the original 2010s-era trials? The fact that researchers are still running this question in 2024 tells you the evidence base is actively being updated, not static. If you're on an integrase inhibitor and considering tesamorelin, this is the specific study to ask your prescriber about, more relevant to your situation than the original pooled phase 3 data alone.

What's the dosing behind these results, and does it match how it's used off-label?

The FDA-approved dose studied in the phase 3 trials is a daily subcutaneous injection, and the population pharmacokinetic work shows clearance is affected by body weight, sex, and renal function ^[11]. If you want the specifics on units, reconstitution, and injection technique, see our tesamorelin dosage guide and the tesamorelin dosage calculator. A post hoc analysis of the phase III trial looked at outcomes in people with and without dorsocervical fat (the 'buffalo hump' associated with lipodystrophy) and found the treatment effect held regardless of that baseline characteristic . That's a useful data point if you're wondering whether your specific fat distribution pattern matters for whether tesamorelin will do anything for you. Off-label use, meaning use outside HIV-associated lipodystrophy, is common in longevity and aesthetic medicine contexts, but it isn't backed by trials of the same size or rigor. The dose, frequency, and expected timeline in those off-label contexts are extrapolated from the approved-indication trials, not independently proven for a general population.

What side effects show up in the before-and-after story that people don't talk about?

Injection site reactions are the most common side effect reported across the phase 3 program and its extension data . Beyond that, because tesamorelin raises IGF-1 (insulin-like growth factor 1) through GH stimulation, monitoring for glucose changes matters, something reviewed in detail in pharmacology summaries of the drug ^[13][14]. A 2011 review in Drugs summarizing tesamorelin's role in HIV-associated lipodystrophy management flagged the general tolerability profile as favorable relative to its benefit in the approved population, but that's a relative statement specific to that population and that trial data, not a blanket safety claim for all uses ^[13]. For the fuller rundown, including what to watch for and when to call your prescriber, see our dedicated page on tesamorelin peptide side effects.

How is tesamorelin sourced, and does that affect what results you can expect?

Tesamorelin as Egrifta is an FDA-approved product with a defined manufacturing and quality standard behind it, tracked in the FDA's own drug approval database [Drugs@FDA]. Compounded versions of tesamorelin exist outside that approval, and the regulatory status of bulk tesamorelin for compounding is governed by the FDA's bulk drug substances rules under section 503A and the corresponding 503B list for outsourcing facilities . This matters for before-and-after expectations because a compounded product's purity, concentration accuracy, and consistency aren't guaranteed the same way an FDA-approved product's are. If your results seem to differ wildly from what a friend reports, sourcing and dosing accuracy are a real variable, more than individual biology. Tesamorelin Co's editorial position is straightforward: understand which product category you're actually getting before you judge whether the 'results' you're seeing match what the trials showed. For details on typical costs across sourcing options, see our tesamorelin cost breakdown, and always work through a provider-reviewed pathway to a legitimate fulfilling pharmacy rather than an unverified seller.

Where does tesamorelin fit against other peptides people compare it to?

A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons on therapeutic peptides in orthopaedics gives useful context for how tesamorelin sits relative to other peptides being studied for musculoskeletal and metabolic goals, noting the general state of evidence and regulatory challenges across the peptide category ^[15]. A companion primer in the American Journal of Sports Medicine aimed at orthopaedic and sports medicine physicians makes a similar point: injectable peptide therapies vary enormously in evidence quality, and tesamorelin is unusual in actually having FDA approval and phase 3 data behind it ^[16]. A 2026 Sports Medicine review on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is worth reading if you're comparing tesamorelin to other GH-axis peptides marketed for body composition, since it lays out safety and efficacy data across the category rather than for one drug alone ^[17]. Tesamorelin's approval status, tied to a narrow HIV lipodystrophy indication, puts it in a different evidence tier than most peptides sold for general fat loss, which typically have no phase 3 data at all. | Peptide category | FDA approval status | Phase 3 RCT evidence | Approved indication |

Frequently asked questions

How long does it take to see results from tesamorelin?

The phase 3 trials measured their primary visceral fat endpoint at 26 weeks (about 6 months) ^[24]. Some inflammatory marker changes tracked earlier, within the first three months ^[26]. Don't expect visible or measurable change in the first few weeks; the trial data doesn't support that timeline.

What do tesamorelin before and after pictures actually show?

Trial evidence measured visceral fat by CT scan, not by photograph ^[24]. Photos online often mix tesamorelin with diet, training, or other compounds, so they don't isolate the drug's actual effect. Be skeptical of any photo pair claiming dramatic change in under 8-12 weeks; that's faster than the trial data supports.

Does tesamorelin actually reduce belly fat you can see, or just internal fat?

Primarily internal, visceral fat around the organs, not the subcutaneous fat you can pinch ^[24]. Waist circumference did show secondary improvement in trials, but the dominant, best-documented effect is the roughly 15-18% VAT reduction measured by CT scan, not a visible six-pack transformation.

What results did the tesamorelin phase 3 trials actually find?

The pooled phase 3 analysis in HIV-associated lipodystrophy found meaningful visceral adipose tissue reduction versus placebo over 26 weeks, with a safety extension confirming the effect held over longer use ^[24]. This is the core evidence behind the FDA approval for that specific indication.

Is tesamorelin approved for general fat loss or just HIV lipodystrophy?

Only for HIV-associated lipodystrophy, specifically reduction of excess abdominal visceral fat ^[3][4]. Any use for general fat loss, athletic performance, or anti-aging is off-label, meaning it's outside what the FDA reviewed and approved, and it isn't backed by the same phase 3 evidence.

Does tesamorelin help with liver fat too?

Yes. A randomized, double-blind trial in The Lancet HIV found tesamorelin reduced hepatic fat fraction in people with HIV-associated NAFLD compared to placebo ^[20]. This liver fat effect is separately documented from the visceral fat effect and has its own transcriptomic and proteomic mechanism studies ^[12][18].

What happens to results if you stop taking tesamorelin?

Durability data is limited outside trial extensions, but GHRH analogue pharmacology suggests benefits depend on continued GH stimulation, so effects likely reverse once treatment stops ^[24]. This is not documented as a one-time reset; it functions more like an ongoing therapy for as long as you use it.

Does tesamorelin work the same way for people on newer HIV medications?

A 2024 study in AIDS specifically examined tesamorelin's efficacy and safety in people on integrase inhibitors, a newer drug class linked to its own weight and metabolic changes ^[7]. This is an active research question, and it's a relevant one to raise with a prescriber if you're on a modern HIV regimen.

What's the most common side effect people report with tesamorelin?

Injection site reactions are the most frequently reported side effect across the phase 3 program and its safety extension data ^[24]. Because the drug raises IGF-1 through GH stimulation, glucose monitoring is also part of standard safety review ^[10][11]. See our tesamorelin peptide side effects page for the full list.

How is tesamorelin dosed in the trials that produced these results?

The approved product is a daily subcutaneous injection; population pharmacokinetic analysis shows clearance varies by body weight, sex, and renal function ^[21]. Exact unit dosing and reconstitution steps are covered in our tesamorelin dosage and reconstitution guides.

Does dorsocervical fat (buffalo hump) affect whether tesamorelin will work?

A post hoc analysis of the phase III trial found the visceral fat treatment effect held whether or not participants had dorsocervical fat at baseline ^[23]. So that specific fat distribution pattern doesn't appear to predict whether you'll respond to treatment.

Is compounded tesamorelin the same as the FDA-approved version, results-wise?

Not necessarily. The FDA-approved product (Egrifta) has a defined quality and manufacturing standard tracked in the FDA's Drugs@FDA database. Compounded tesamorelin falls under separate bulk drug substance rules (21 CFR 216.23, 216.24) and purity or dosing consistency isn't guaranteed the same way, which can affect how closely your results track trial data.

Sources

1. PubMed, Therapeutic Peptides in Orthopaedics (JAAOS Global Research & Reviews, 2026): Reviews the general state of evidence and regulatory challenges across therapeutic peptides used in orthopaedic and metabolic contexts
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (AJSM, 2026): Notes wide variation in evidence quality across injectable peptide therapies marketed to sports medicine patients
3. PubMed, Tesamorelin (2012): Confirms tesamorelin's approved indication is reduction of excess abdominal visceral fat in HIV-associated lipodystrophy
4. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Describes tesamorelin's mechanism as a GHRH analogue stimulating endogenous growth hormone release
5. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): Compares safety and efficacy evidence across approved versus unapproved GH-axis peptides marketed for body composition and performance
6. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024): Examines tesamorelin's efficacy and safety specifically in people on integrase inhibitor HIV regimens
7. PubMed, Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (Journal of Infectious Diseases, 2025): Studies tesamorelin's effect on neurocognitive impairment specifically in HIV patients with abdominal obesity
8. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011): Reviews tesamorelin's tolerability profile relative to its benefit in the approved HIV lipodystrophy population
9. PubMed, Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (Annals of Pharmacotherapy, 2012): Reviews pharmacology including IGF-1 elevation relevant to glucose monitoring during treatment
10. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD (JCI Insight, 2020): Found tesamorelin changed liver gene expression signatures consistent with reduced fat accumulation
11. PubMed, Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021): Reports tesamorelin improves adipose tissue quality independent of the amount of fat reduction
12. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin (Obesity Research & Clinical Practice, 2026): Meta-analysis of RCTs showing trial durations for tesamorelin outcomes cluster around 26 to 52 weeks
13. PubMed, Delineating tesamorelin response pathways in HIV-associated NAFLD (Scientific Reports, 2021): Maps proteomic and transcriptomic pathways involved in tesamorelin's hepatic fat reduction effect
14. PubMed, Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017): Links visceral fat reduction from tesamorelin to improved liver enzyme levels in HIV patients
15. PubMed, Effects of tesamorelin on non-alcoholic fatty liver disease in HIV (The Lancet HIV, 2019): Randomized double-blind multicenter trial found tesamorelin reduced hepatic fat fraction in HIV-associated NAFLD versus placebo
16. PubMed, Population pharmacokinetic analysis of tesamorelin (Clinical Pharmacokinetics, 2015): Shows tesamorelin clearance varies by body weight, sex, and renal function in HIV-infected patients and healthy subjects
17. PubMed, Effect of tesamorelin in people with HIV with and without dorsocervical fat (Journal of Clinical and Translational Science, 2023): Post hoc analysis found the visceral fat treatment effect held regardless of baseline dorsocervical fat status
18. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat, pooled phase 3 analysis (JCEM, 2010): Pooled phase 3 double-blind placebo-controlled trial data showing visceral fat reduction at 26 weeks with safety extension results
19. PubMed, Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat (AIDS, 2011): Found inflammatory marker reductions related to visceral fat loss appearing within the first three months of treatment
20. FDA, Bulk drug substances used in compounding under section 503A: Explains the regulatory framework governing bulk drug substances, including tesamorelin, used in 503A pharmacy compounding
21. eCFR, 21 CFR 216.24, the 503B Bulks List: Sets out the bulk drug substances list applicable to 503B outsourcing facilities compounding tesamorelin products